α-lactalbumin vaccine + Zymosan
Phase 1ActiveDevelopment Stage
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
Oct 1, 2021 → May 1, 2026
About α-lactalbumin vaccine + Zymosan
α-lactalbumin vaccine + Zymosan is a phase 1 stage product being developed by Anixa Biosciences for Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04674306. Target conditions include Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease.
What happened to similar drugs?
1 of 7 similar drugs in Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04674306 | Phase 1 | Active |
Competing Products
9 competing products in Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olanzapine + sugar pill | Eli Lilly | Phase 3 | 40 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 40 |
| Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT | Novartis | Phase 3 | 40 |
| Ranibizumab | Novartis | Phase 3 | 40 |
| Faricimab + Ranibizumab | Roche | Phase 3 | 44 |
| Ipilimumab + Nivolumab + VX15/2503 | Bristol Myers Squibb | Phase 1 | 33 |
| VEGF Trap-Eye (BAY86-5321) | Regeneron Pharmaceuticals | Phase 3 | 40 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 2 | 32 |
| Gadoversetamide | Guerbet | Approved | 33 |